Assembly Biosciences Inc., a biopharmaceutical company operating within the Health Care sector, specifically in the Biotechnology industry, has been making significant strides in the field of infectious diseases. The company is publicly traded on the Nasdaq and is denominated in USD. As of March 17, 2026, the closing price of Assembly Biosciences Inc. was recorded at $27.52. Over the past year, the company’s stock has experienced fluctuations, reaching a 52-week high of $39.71 on November 19, 2025, and a 52-week low of $7.75 on April 6, 2025. The market capitalization of the company stands at approximately $454.58 million.
Assembly Biosciences Inc. is primarily focused on addressing two critical infectious diseases: Hepatitis B virus (HBV) and Clostridium difficile-associated diarrhea (CDAD). The company has developed two proprietary platforms aimed at these conditions. The first platform is an HBV-cure platform, which is centered around oral drugs that employ novel direct-acting mechanisms. This innovative approach aims to provide a potential cure for HBV, a significant global health challenge.
In addition to its work on HBV, Assembly Biosciences Inc. is also advancing an orally-delivered microbiome therapeutics platform designed to treat CDAD. This platform leverages the understanding of the human microbiome to develop treatments that can effectively manage and potentially cure CDAD, a condition that poses a substantial burden on healthcare systems worldwide.
Despite the promising developments in its proprietary platforms, the company’s financial metrics reflect certain challenges. The price-to-earnings (P/E) ratio stands at -5.432, indicating that the company is currently not generating positive earnings. This is not uncommon for biopharmaceutical companies in the development phase, where significant investments in research and development are prioritized over immediate profitability.
Assembly Biosciences Inc. continues to focus on advancing its innovative platforms, with the potential to make substantial contributions to the treatment of infectious diseases. The company’s efforts in developing novel therapeutic approaches for HBV and CDAD highlight its commitment to addressing unmet medical needs and improving patient outcomes in the field of infectious diseases.
